Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

BACKGROUND: Brentuximab vedotin is a CD30-directed antibody-drug conjugate. Retreatment with brentuximab vedotin monotherapy was investigated in patients with CD30-positive Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (ALCL) who relapsed after achieving complete or partial remiss...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartlett, Nancy L, Chen, Robert, Fanale, Michelle A, Brice, Pauline, Gopal, Ajay, Smith, Scott E, Advani, Ranjana, Matous, Jeffrey V, Ramchandren, Radhakrishnan, Rosenblatt, Joseph D, Huebner, Dirk, Levine, Pamela, Grove, Laurie, Forero-Torres, Andres
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994656/
https://www.ncbi.nlm.nih.gov/pubmed/24642247
http://dx.doi.org/10.1186/1756-8722-7-24

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994656/
https://www.ncbi.nlm.nih.gov/pubmed/24642247
http://dx.doi.org/10.1186/1756-8722-7-24

Ejemplares similares